Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study-Reference-Cited by-同舟云学术

Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study

Published:2007-03 Issue:3 Volume:8 Page:203-211
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gong Yun,Yan Kai,Lin Feng,Anderson Keith,Sotiriou Christos,Andre Fabrice,Holmes Frankie A,Valero Vicente,Booser Daniel,Pippen John E,Vukelja Svetislava,Gomez Henry,Mejia Jaime,Barajas Luis J,Hess Kenneth R,Sneige Nour,Hortobagyi Gabriel N,Pusztai Lajos,Symmans W Fraser

Publisher

Elsevier BV

Subject

Oncology

Reference34 articles.

1. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831;Roche;J Natl Cancer Inst,2002

2. Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status;Layfield;Breast J,2003

3. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems;Rhodes;J Clin Pathol,2000

4. Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists;Rudiger;Am J Surg Pathol,2002

5. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study;Bonneterre;J Clin Oncol,2000

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of recurrence prediction ability of EndoPredict® using microarray data from fresh frozen tissues in ER-positive, HER2-negative breast cancer and indication expansion of EndoPredict® from microarray data from fresh-frozen to FFPE tissues;Breast Cancer;2024-04-08

2. Quantitative expression of oestrogen receptor in breast cancer: Clinical and molecular significance;European Journal of Cancer;2024-01

3. Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay;The Oncologist;2023-09-01

4. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial;Nature Medicine;2023-07-24

5. Automated Classification of Breast Cancer Across the Spectrum of ERBB2 Expression Focusing on Heterogeneous Tumors With Low Human Epidermal Growth Factor Receptor 2 Expression;JCO Clinical Cancer Informatics;2023-07